STTK
Shattuck Labs, Inc. Common StockstockNASDAQ
shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. compounds derived from shattuck's proprietary agonist redirected checkpoint, arc®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. the company's lead wholly owned program, sl-172154 (sirpα-fc-cd40l), which is designed to block the cd47 immune checkpoint and simultaneously agonize the cd40 pathway, is being evaluated in a phase 1 trial. a second compound, sl-279252 (pd1-fc-ox40l), is being evaluated in a phase 1 trial in collaboration with takeda pharmaceuticals. additionally, the company is advancing a proprietary gamma delta t cell engager, gadlen™, platform, which is designed to bridge gamma delta t cells to tumor antigens for the treatment of patients with cancer. shattuck has offices in both austin, tex
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 4.81 | 2026-11-12 | -7.07% | -2.012 |
| 1M | 5.37 | 2026-10-19 | -16.76% | 2.165 |
| 3M | 7.66 | 2026-08-19 | -41.65% | 1.781 |
| 6M | 5.79 | 2026-05-19 | -22.80% | 1.466 |
| 1Y | 1.96 | 2025-11-19 | +128.06% | 1.281 |
| 2Y | 1.14 | 2024-11-19 | +292.11% | — |
| 5Y | 9.40 | 2021-11-19 | -52.45% | 1.394 |
Shattuck Labs, Inc. Common Stock (NASDAQ:STTK) stock price today is $4.47, and today's volume is 2,075,320. STTK is down 2.614% today. The 30 day average volume is 1.08M. STTK market cap is $455.24M with 101.84M shares outstanding.